Valuation: Denali Therapeutics Inc.

Market Cap 2.99B 2.66B 2.46B 2.23B 4.2B 282B 4.25B 29.54B 11.59B 148B 11.2B 10.97B 472B P/E 2026 *
-8.21x
P/E 2027 * -8.1x
Enterprise Value 2.28B 2.03B 1.88B 1.7B 3.2B 215B 3.24B 22.53B 8.84B 113B 8.54B 8.37B 360B EV / Sales 2026 *
45x
EV / Sales 2027 * 17.1x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.32%
1 week+4.53%
Current month-9.63%
1 month-8.74%
3 months-21.61%
6 months-7.20%
Current year+13.14%
1 week 17.33
Extreme 17.33
19.35
1 month 17.33
Extreme 17.33
21.51
Current year 15.34
Extreme 15.34
27.3
1 year 13.75
Extreme 13.75
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 A Sell

Chief Technology Officer

-1,654 0.0010%
9/2/26 A Sell

Director

-11,439 0.0072%
9/1/26 A Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%+4.53%+10.14%+1.97% 2.99B
-0.21%-4.43%+44.40%+74.13% 66.22B
-3.17%+0.44%+7.43%+68.97% 55.2B
+1.12%+4.14%+12.29%+91.94% 52.79B
+3.28%+5.58%+26.51%+50.05% 45.53B
+0.51%+9.95%+22.40%+133.92% 43.94B
-1.15%+0.39%+263.21%+594.60% 41.64B
+0.10%+9.90%+16.11%+59.33% 34B
-8.38%-6.95%+26.35%-1.93% 25.84B
+0.65%+4.47%+37.60%+27.45% 23.51B
Average -1.16%+4.12%+46.64%+110.04% 39.17B
Weighted average by Cap. -0.87%+3.73%+49.26%+125.40%

Financials

2026 *2027 *
Net sales 50.65M 45.14M 41.79M 37.82M 71.25M 4.78B 72.09M 501M 197M 2.51B 190M 186M 8.01B 131M 116M 108M 97.54M 184M 12.33B 186M 1.29B 507M 6.48B 490M 480M 20.65B
Net income -445M -396M -367M -332M -626M -41.98B -633M -4.4B -1.73B -22.06B -1.67B -1.63B -70.31B -451M -402M -372M -337M -634M -42.54B -642M -4.46B -1.75B -22.36B -1.69B -1.66B -71.25B
Net Debt -708M -631M -584M -529M -996M -66.85B -1.01B -7.01B -2.75B -35.14B -2.66B -2.6B -112B -749M -667M -618M -559M -1.05B -70.65B -1.07B -7.41B -2.91B -37.14B -2.81B -2.75B -118B
Projected Income Statement - Annual - Denali Therapeutics Inc.
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
21/10/26 $18.68 -1.32% 1,429,264
20/10/26 $18.93 +4.93% 1,824,103
19/10/26 $18.04 +2.44% 2,688,860
16/10/26 $17.61 -3.98% 2,304,311
15/10/26 $18.34 +2.63% 1,566,182
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Denali Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
18.68USD
Average target price
35.50USD
Spread / Average Target
+90.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Denali Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DNLI Stock